Abstract
Background
In patients requiring hemodialysis, the extracorporeal circuit is expected to remove the majority of serum levetiracetam. The preferred levetiracetam dosing regimen in critically ill patients exhibiting complex pharmacokinetic profiles undergoing hemodialysis is unknown. The objective of this case is to describe levetiracetam pharmacokinetics in a critically ill anephric patient receiving intermittent hemodialysis.
Methods
This is a case report of a single patient.
Results
A 43-year-old anephric female was admitted to the intensive care unit for concerns of new onset seizure activity. She was loaded with 2000 mg levetiracetam followed by a 750 mg daily maintenance dose. The levetiracetam volume of distribution was 0.48 L/kg, and the interdialytic elimination half-life was 31 h. Hemodialysis removed nearly 85% of serum levetiracetam, and the patient exhibited slightly higher than expected non-renal elimination. Pharmacokinetic simulations identified 500 mg daily with 750 mg post-dialysis supplements as the regimen most likely to reduce variability in serum levetiracetam concentrations and achieve levels in the therapeutic range.
Conclusion
Substantial elimination of levetiracetam by hemodialysis occurred in this case, and non-renal clearance was slightly higher than in previous reports. Insufficient intradialytic or post-dialysis levetiracetam concentrations may place patients at risk of breakthrough seizures. This case indicates that dialysis patients on levetiracetam may require higher post-dialysis supplemental doses than currently recommended and tailored therapy supported by therapeutic drug monitoring.
Similar content being viewed by others
References
Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocritical Care. 2012;17(1):3–23.
Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American epilepsy society. Epilepsy Curr. 2016;16(1):48–61.
Hovinga C. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy. 2001;21(11):1375–88.
Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85:77–85.
Wright C, Downing J, Mungall D, et al. Clinical pharmacology and pharmacokinetics of levetiracetam. Front Neurol. 2013;4:192.
Nei SD, Wittwer ED, Kashani KB, Frazee EN. Levetiracetam pharmacokinetics in a patient receiving continuous venovenous hemofiltration and venoarterial extracorporeal membrane oxygenation. Pharmacotherapy. 2015;35(8):e127–30.
New AM, Nei SD, Kashani KB, Rabinstein AA, Frazee EN. Levetiracetam pharmacokinetics during continuous venovenous hemofiltration and acute liver dysfunction. Neurocritical Care. 2016;25(1):141–4.
Louie JM, Raphael KL, Barker B. Levetiracetam use with continuous renal replacement therapy. Ann Pharmacother. 2015;49(9):1079–80.
le Noble JLML, Foudraine NA, Kornips FHM, van Dam DGHA, Neef C, Janssen PKC. Extracorporeal clearance of levetiracetam during continuous venovenous hemofiltration in a critically ill patient and new dosing recommendation. J Clin Pharmacol. 2016;57(4):536–7.
Van Matre ET, Mueller SW, Fish DN, et al. Levetiracetam pharmacokinetics in a patient with intracranial hemorrhage undergoing continuous veno-venous hemofiltration. Am J Case Rep. 2017;18:458–62.
Shiue HJ, Taylor M, Sands KA. Comparison of levetiracetam dosing regimens in end-stage renal disease patients undergoing intermittent hemodialysis. Ann Pharmacother. 2017. doi:10.1177/1060028017713294.
Levetiracetam [prescribing information]. Smyrna, GA: UCB, Inc; March 2015.
Bauer LA. Applied clinical pharmacokinetics. 2nd ed. New York: McGraw-Hill Medical; 2008.
Yamamoto J, Toublanc N, Kumagai Y, Stockis A. Levetiracetam pharmacokinetics in Japanese subjects with renal impairment. Clin Drug Investig. 2014;34(11):819–28.
French J. Use of levetiracetam in special populations. Epilepsia. 2001;42(Suppl 4):40–3.
Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther. 2008;83(6):898–903.
Thomson BKA, Nolin TD, Velenosi TJ, et al. Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. Am J Kidney Dis. 2015;65(4):574–82.
Company-Albir MJ, Ruíz-Ramos J, Solana Altabella A, Marqués-Miñana MR, Vicent C, Poveda JL. Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: case report. J Clin Pharm Ther. 2017. doi:10.1111/jcpt.12568.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical Approval
All applicable institutional and/or national guidelines for the care and use of animals were followed.
Informed Consent
A waiver of informed consent was provided.
Rights and permissions
About this article
Cite this article
Wieruszewski, P.M., Kashani, K.B., Rabinstein, A.A. et al. Levetiracetam Pharmacokinetics in a Critically Ill Anephric Patient on Intermittent Hemodialysis. Neurocrit Care 28, 243–246 (2018). https://doi.org/10.1007/s12028-017-0441-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12028-017-0441-4